Siglec-15/CD33L3, His & Avi, Human
Siglec-15/CD33L3, His & Avi, Human

Immobilized Siglec-15/CD33L3, His & Avi, Human, His Tag at 0.5 μg/ml (100 μL/well) on the plate. Dose response curve for Anti-Siglec-15 Antibody, hFc Tag with the EC50 of 4.6 ng/ml determined by ELISA.

Siglec-15/CD33L3, His & Avi, Human

The purity of Siglec-15/CD33L3, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

Siglec-15/CD33L3, His & Avi, Human

Siglec-15/CD33L3, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Siglec-15/CD33L3, His & Avi, Human

Siglec-15 is a transmembrane glycoprotein in the Siglec family of sialic acid-binding immune regulatory molecules. Mature human Siglec-15 consists of a 244 amino acid extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.
Z05819
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Siglec-15/CD33L3 (Phe20-Thr263)
Accession # Q6ZMC9		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95.0% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Siglec-15/CD33L3, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti­-Siglec­15-Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 29.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 30-38 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 20mM NaAC (pH 5.0).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • Siglec-15/CD33L3, His & Avi, Human
    • Siglec-15/CD33L3, His & Avi, Human

    Immobilized Siglec-15/CD33L3, His & Avi, Human, His Tag at 0.5 μg/ml (100 μL/well) on the plate. Dose response curve for Anti-Siglec-15 Antibody, hFc Tag with the EC50 of 4.6 ng/ml determined by ELISA.

  • Siglec-15/CD33L3, His & Avi, Human
    • Siglec-15/CD33L3, His & Avi, Human

    The purity of Siglec-15/CD33L3, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • Siglec-15/CD33L3, His & Avi, Human
    • Siglec-15/CD33L3, His & Avi, Human

    Siglec-15/CD33L3, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Siglec-15 is a transmembrane glycoprotein in the Siglec family of sialic acid-binding immune regulatory molecules. Mature human Siglec-15 consists of a 244 amino acid extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.
Synonyms CD33 molecule-like 3; CD33L3; HsT1361; Siglec15; CD33 antigen-like 3; SIGLEC-15

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.